Literature DB >> 17393302

Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers.

Y Wang1, F Ylera, M Boston, S-G Kang, J L Kutok, A J P Klein-Szanto, R P Junghans.   

Abstract

Breast tumors with prominent plasma cell (PC) infiltrates often have a more favorable natural course that may plausibly be mediated by anti-tumor activity of the elicited antibodies. These breast tumor-associated PCs are typically IgG dominant in contrast to normal breast PCs, which are mainly IgA. It is our hypothesis that this PC infiltration represents a host immune response that is driven by one or more tumor antigens. Previously, we and others showed that medullary carcinoma (MC) had a focused repertoire and features suggestive of a protein antigen driven response. Infrequently, non-MC, not otherwise specified (NOS) breast tumors may exhibit heavy PC infiltrations, also of IgG isotype. In this first characterization of this favorable prognosis NOS subgroup, IgG heavy chain (Hc) and light chain (Lc) variable (V) regions from three PC-infiltrated NOS tumors were randomly cloned and sequenced. We found biased (V) gene usage by the infiltrating PCs and somatic hypermutation in the rearranged Ig Hc and Lc V regions that were compatible with antigenic selection of the progenitor B cells. The antibody response of NOS infiltrated breast cancer is repertoire-focused, with 13-68% of isolates being clonally reiterated in the samples. Each NOS patient used distinct Hc V-D-J and Lc V-J rearrangements, with her own immune response "footprint," but the overall pattern of gene usage followed that typical of exogenous antigen-induced immune responses. The data are consistent with the hypothesis that PC infiltrates infrequently arising in NOS tumors, as previously inferred for MC, are in response to one or more breast cancer-associated protein tumor antigens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393302     DOI: 10.1007/s10549-006-9409-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

1.  Prognostic Factors and Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancer.

Authors:  Özgecan Dülgar; Şennur İlvan; Zeynep Hande Turna
Journal:  Eur J Breast Health       Date:  2020-04-17

2.  Immunoglobulin kappa C predicts overall survival in node-negative breast cancer.

Authors:  Zonglin Chen; Aslihan Gerhold-Ay; Susanne Gebhard; Daniel Boehm; Christine Solbach; Antje Lebrecht; Marco Battista; Isabel Sicking; Christina Cotarelo; Cristina Cadenas; Rosemarie Marchan; Joanna D Stewart; Mathias Gehrmann; Heinz Koelbl; Jan G Hengstler; Marcus Schmidt
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

Review 3.  Heterogeneity and Functions of Tumor-Infiltrating Antibody Secreting Cells: Lessons from Breast, Ovarian, and Other Solid Cancers.

Authors:  Yasmine Lounici; Olivia Le Saux; Gabriel Chemin; Pauline Wajda; Sarah Barrin; Justine Berthet; Christophe Caux; Bertrand Dubois
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

4.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

Review 5.  The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities.

Authors:  Nicole J Flynn; Rajasekharan Somasundaram; Kimberly M Arnold; Jennifer Sims-Mourtada
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.864

Review 6.  Role of immune cells in pancreatic cancer from bench to clinical application: An updated review.

Authors:  Jae Hyuck Chang; Yongjian Jiang; Venu G Pillarisetty
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.